Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling

He, Zheng; Zhao, Tingting; Jin, Feng; Li, Ji‐Guang; Xu, Yingying; Dong, Huiting; Li, Qun; Xing, Peng; Zhu, Guolian; Xu, Hao; Zhang, Miao

doi:10.1016/j.bbrc.2018.06.159

Cited by 15 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More specifically, immunohistochemical studies of RASSF6 in 95 BC tumor samples revealed low expression of RASSF6 in 42 cases. Especially in TNBC, RASSF6 downregulation was stronger [39]. RASSF6 downregulates YAP1 by upregulating MST1/2 and LATS1 phosphorylation, depicting a direct association of RASSF6 with Hippo signaling during BC tumorigenesis [39].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review

Kyriazoglou¹,

Liontos²,

Zakopoulou³

et al. 2020

Breast Care

View full text Add to dashboard Cite

Background: The Hippo pathway is a developmental pathway recently discovered in Drosophila melanogaster; in mammals it normally controls organ development and wound healing. Hippo signaling is deregulated in breast cancer (BC). MST1/2 and LATS1/2 kinases are the upstream molecular elements of Hippo signaling which phosphorylate and regulate the two effectors of Hippo signaling, YAP1 and TAZ cotranscriptional activators. The two molecular effectors of the Hippo pathway facilitate their activity through TEAD transcription factors. Several molecular pathways with known oncogenic functions cross-talk with the Hippo pathway. Methods: A systematic review studying the correlation of the Hippo pathway with BC tumorigenesis, prognosis, and treatment was performed. Results: Recent literature highlights the critical role of Hippo signaling in a wide spectrum of biological mechanisms in BC. Discussion: The Hippo pathway has a crucial position in BC molecular biology, cellular behavior, and response to treatment. Targeting the Hippo pathway could potentially improve the prognosis and outcome of BC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Especially in TNBC, RASSF6 downregulation was stronger [39]. RASSF6 downregulates YAP1 by upregulating MST1/2 and LATS1 phosphorylation, depicting a direct association of RASSF6 with Hippo signaling during BC tumorigenesis [39]. Epigenetic regulation of RASSF1A through promoter regulation reduces pYAP and prevents invasion in BC tumors [86].…”

Section: Discussionmentioning

confidence: 99%

The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review

Kyriazoglou¹,

Liontos²,

Zakopoulou³

et al. 2020

Breast Care

View full text Add to dashboard Cite

show abstract

“…He et al found that Ras association domain family member 6 (RASSF6) overexpression could increase cisplatin-induced apoptosis, while depletion of RASSF6 had the opposite effect in breast cancer cells [100]. The authors observed that RASSF6 decreased cellular YAP concentration and activated the Hippo signaling pathway by upregulating the phosphorylation of MST1/2 and LATS1.…”

Section: A Multitude Of Molecules Regulate Apoptosis and Hippo-yapmentioning

confidence: 99%

The Ambivalent Function of YAP in Apoptosis and Cancer

Zhang

Abdelrahman

Vollmar

et al. 2018

IJMS

View full text Add to dashboard Cite

Yes-associated protein, a core regulator of the Hippo-YAP signaling pathway, plays a vital role in inhibiting apoptosis. Thus, several studies and reviews suggest that yes-associated protein is a good target for treating cancer. Unfortunately, more and more evidence demonstrates that this protein is also an essential contributor of p73-mediated apoptosis. This questions the concept that yes-associated protein is always a good target for developing novel anti-cancer drugs. Thus, the aim of this review was to evaluate the clinical relevance of yes-associated protein for cancer pathophysiology. This review also summarized the molecules, processes and drugs, which regulate Hippo-YAP signaling and discusses their effect on apoptosis. In addition, issues are defined, which should be addressed in the future in order to provide a solid basis for targeting the Hippo-YAP signaling pathway in clinical trials.

show abstract

“…Accumulating evidence has suggested that activation of the Hippo-YAP signaling pathway plays an antitumor role in different types of cancer, including gastric cancer, breast cancer, and prostate cancer. [31][32][33] The Hippo-YAP signaling pathway plays a critical role in mediating VEGF-induced angiogenesis, where knockdown or inhibition of YAP/TAZ was found to result in a significant decrease in angiogenesis triggered by VEGF. 34 In the current study, LATS2 overexpression also led to low expression of VEGF, suggesting that LATS2 over-expression could suppress angiogenesis.…”

Section: Yap/taz Figurementioning

confidence: 99%

Downregulation of microRNA-224-3p Hampers Retinoblastoma Progression via Activation of the Hippo-YAP Signaling Pathway by Increasing LATS2

Song

Huang

Zhang

et al. 2020

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling

Cited by 15 publications

References 22 publications

The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review

The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review

The Ambivalent Function of YAP in Apoptosis and Cancer

Downregulation of microRNA-224-3p Hampers Retinoblastoma Progression via Activation of the Hippo-YAP Signaling Pathway by Increasing LATS2

Contact Info

Product

Resources

About